00:00
00:00
00:00
ValiRx - VAL201 Update

ValiRx announces that in addition to pharmacokinetic and toxicology data, clinical trial results show VAL201 behaves as predicted in reducing prostate cancer progression. Dr George Morris, COO, discusses the significance of this announcement and the next stage of development.

Dr George Morris
Chief Operating Officer

Company Events - VALIRX PLC